Peginterferon beta-1a – nowa postać interferonu beta-1a

• Authors: Zdzisław Maciejek , Anna Niezgodzińska-Maciejek

Title variants

EN

Peginterferon beta-1a – a new form of interferon beta-1a

• Languages of publication: EN PL

Abstracts

EN

In 2014 after phase 3 ADVANCE clinical study was finished, a new, pegylated form of interferon beta-1a with less frequent dosing was accepted for treatment in relapsing-remitting multiple sclerosis. One thousand five hundred and twelve patients with relapsing-remitting multiple sclerosis were enrolled to the ADVANCE study from 183 sites in 26 countries (500 to the placebo group, 512 to the 125 μg subcutaneous peginterferon beta-1a every 2 weeks group and 500 to the 125 μg subcutaneous peginterferon beta-1a every 4 weeks group). The investigated groups were similar in terms of age, sex, duration of the disease and disability rated using the Expanded Disability Status Scale. The primary and secondary endpoints were efficacy and safety of 2-year peginterferon beta-1a treatment in patients with relapsing-remitting multiple sclerosis compared to the placebo group, which after 1 year also received peginterferon beta-1a 125 μg every 2 or every 4 weeks. The results from the 2-year ADVANCE study demonstrate efficacy of treatment with peginterferon beta-1a 125 μg administered subcutaneously every 2 weeks compared with placebo: significantly reduced annualized relapse rate (by 37%), the number of new/newly enlarged T2 lesions (by 67%), the risk of relapse (by 39%) and the risk of 12-week sustained disability progression (by 33%). The most common adverse events (94% of patients) associated with peginterferon beta-1a treatment were: injection site reactions, flu-like symptoms, pyrexia and headache. Sixteen percent of patients taking the study drug every 2 weeks and 22% of patients taking the study drug every 4 weeks reported serious adverse events; relapse, pneumonia and urinary tract infections were the most common. Interpretation: the treatment with peginterferon beta-1a with less frequent administration is effective, well tolerated and safe for patients with relapsing-remitting multiple sclerosis.

PL

W 2014 roku, po zakończeniu próby klinicznej III fazy ADVANCE, do leczenia postaci rzutowo-remisyjnej stwardnienia rozsianego wprowadzono nową pegylowaną postać interferonu beta-1a o wydłużonym czasie działania. Do badania zakwalifikowano 1512 chorych ze 183 ośrodków z 26 krajów (500 uczestników przyjmowało placebo, 512 – peginterferon beta-1a w dawce 125 μg podawany podskórnie co 2 tygodnie, 500 – peginterferon beta-1a w dawce 125 μg podawany podskórnie co 4 tygodnie). Grupy były zbliżone pod względem wieku, płci, czasu trwania choroby i niepełnosprawności ocenianej w Expanded Disability Status Scale. Cel badania stanowiła ocena skuteczności i bezpieczeństwa pegylowanego interferonu beta-1a po 2 latach terapii w porównaniu z grupą placebo, która w drugim roku również otrzymywała ten lek. Skuteczność peginterferonu beta-1a podawanego co 2 tygodnie w porównaniu z placebo przejawiała się redukcją rocznego wskaźnika rzutów (o 37%), liczby nowych lub powiększonych ognisk T2-zależnych (o 67%), ryzyka wystąpienia rzutu (o 39%) i ryzyka utrwalonej 12-tygodniowej progresji niepełnosprawności (o 33%). Najczęstsze działania niepożądane towarzyszące kuracji (94% chorych) to odczyn w miejscu wkłucia, objawy grypopodobne, gorączka i bóle głowy. U 16% osób przyjmujących lek co 2 tygodnie i 22% otrzymujących go co 4 tygodnie odnotowano poważne objawy niepożądane (rzuty, zapalenie płuc, infekcje dróg moczowych). Reasumując: leczenie peginterferonem beta-1a cechowały skuteczność, dobra tolerancja i bezpieczeństwo.

Keywords

EN

MRI; NEDA; RRMS; peginterferon beta-1a

Discipline

• MEDICINE: MEDICINE

• Journal: Aktualności Neurologiczne
• Year: 2015
• Volume: 15
• Issue: 3
• Pages: 135–138

Contributors

author

Zdzisław Maciejek

• Klinika Neurologiczna, 10. Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w Bydgoszczy, Polska,

author

Anna Niezgodzińska-Maciejek

• Klinika Neurologiczna, 10. Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w Bydgoszczy, Polska

References

• Arnold D, Calabresi P, Kieseier B et al.: Magnetic resonance imaging results from the first year of the ADVANCE study, a pivotal phase 3 trial of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis. Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Copenhagen, Denmark, 2013. P.989.
• Arnold D, You X, Shang S et al.: Long-term efficacy in MRI and no evidence of disease activity outcomes in patients with relapsingremitting multiple sclerosis treated with peginterferon beta-1a. Presented at the American Academy of Neurology’s 67th Annual Meeting; Washington, USA, 2015. P7.266.
• Calabresi PA, Kieseier BC, Arnold DL et al.; ADVANCE Study Investigators: Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13: 657–665.
• Calabresi P, Kieseier B, Arnold D et al.: Clinical efficacy and safety of peginterferon beta-1a in relapsing multiple sclerosis: data from the pivotal phase 3 ADVANCE study. Presented at the American Academy of Neurology’s 65th Annual Meeting; San Diego, USA, 2013a. S31.006.
• Calabresi P, Kieseier B, Arnold D et al.: Peginterferon beta-1a provides improvements in clinical and radiological disease activity in relapsing-remitting multiple sclerosis: year 1 findings from the phase 3 ADVANCE study. Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Copenhagen, Denmark, 2013b. P.514.
• Durelli L, Verdun E, Barbero P et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453–1460.
• Edan G, Kappos L, Montalban X et al.: Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2014; 85: 1183–1189.
• Goelz SE, Dupont S, Goyal J et al.: Repeated treatment with interferon beta-1a in vitro results in the attenuation of cellular responsiveness. Presented at the American Academy of Neurology’s 54th Annual Meeting; Denver, USA, 2002. PO6.049. Neurology 2002; 58 (suppl 3): A 446.
• Hu X, Miller L, Richman S et al.: A novel PEGylated interferon beta- 1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 2012; 52: 798–808.
• Imitola J, Racke MK: Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? JAMA Neurol 2015; 72: 145–147.
• Kappos L, Clanet M; the European Interferon Beta-1a Dose-Comparison Study Group: Sustained efficacy of interferon beta-1a in relapsing multiple sclerosis: four-year results from the European Dose-Comparison Study. Presented at the American Academy of Neurology’s 54th Annual Meeting; Denver, USA, 2002. PO6.085. Neurology 2002; 58 (suppl 3): A460.
• Kieseier B, Arnold DL, Newsome SD et al.: In relapsing multiple sclerosis, peginterferon beta-1a reduces MRI lesions following relapses. Presented at the American Academy of Neurology’s 67th Annual Meeting; Washington, USA, 2015a. P7.256.
• Kieseier BC, Arnold DL, Balcer LJ et al.: Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2015b; 21: 1025–1035.
• Kieseier BC, Scott TF, Newsome SD et al.: Peginterferon beta-1a may improve recovery following relapse: data from the pivotal phase 3 ADVANCE study in patients with relapsing-remitting multiple sclerosis. Presented at the American Academy of Neurology’s 66th Annual Meeting; Philadelphia, USA, 2014. S4.003.
• Kinkel RP, Kollman C, O’Connor P et al.; CHAMPIONS Study Group: IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678–684.
• Limmroth V, Putzki N, Kachuck NJ: The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord 2011; : 281–296.
• Newsome SD, Kieseier BC, Shang S et al.: Peginterferon beta-1a is effective as early as twelve weeks following treatment initiation in patients with relapsing multiple sclerosis. Presented at the American Academy of Neurology’s 67th Annual Meeting; Washington, USA, 2015. S4.001.
• O’Connor P, Kinkel RP, Kremenchutzky M: Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler 2009; 15: 728–734.
• Panitch H, Goodin D, Francis G et al.; EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group: Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005; 239: 67–74.
• Radue EW, Kappos L, Simonian N et al.: MRI results of the European Interferon Beta-1a Dose-Comparison Study. Presented at the American Academy of Neurology’s 54th Annual Meeting; Denver, USA, 2002. PO3.069. Neurology 2002; 58 (suppl 3): A204.
• Rotstein DL, Healy BC, Malik MT et al.: Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72: 152–158.
• Simon JH, Kinkel RP, Kollman C et al.; CHAMPIONS Investigators Group: Ten-year follow-up of the ‘minimal MRI lesion’ subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Mult Scler 2015; 21: 415–422.
• Sormani MP, Arnold DL, De Stefano N: Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014; 75: 43–49.
• Vollmer T, Signorovitch J, Huynh L et al.: The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis. J Neurol Sci 2015; 357: 8–18.
• Zivadinov R, Reder AT, Filippi M et al.: Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136–144.

• Document Type: review